Sökning: id:"swepub:oai:lup.lub.lu.se:064fbbc9-4a88-4c4c-bcf7-6c11bdc78bb0" >
Effects of adjuvant...
-
Ekholm, M.Linköpings universitet,Linköping University,Lund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Personalized Breast Cancer Treatment,Lund University Research Groups,Jönköping County Council,Institutionen för klinisk och experimentell medicin,Medicinska fakulteten,Dept Oncol, Jönköping, Sweden; Lund Univ, Sweden
(författare)
Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial
- Artikel/kapitelEngelska2019
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:064fbbc9-4a88-4c4c-bcf7-6c11bdc78bb0
-
https://lup.lub.lu.se/record/064fbbc9-4a88-4c4c-bcf7-6c11bdc78bb0URI
-
https://doi.org/10.1016/j.ejca.2018.12.034DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-155552URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Funding Agencies|Futurum-the Academy of Health and Care; Jonkoping County Council; Foundation for Clinical Cancer Research in Jonkoping; FORSS (Medical Research Council of Southeast Sweden); Gunnar Nilsson Cancer Foundation; Mrs. Berta Kamprad Foundation; Anna and Edwin Bergers Foundation; Swedish Cancer and Allergy Foundation; Governmental Funding of Clinical Research within the Swedish National Health Service; Swedish Cancer Society
-
Aims: The primary aim was to compare 2 years of adjuvant tamoxifen versus no systemic treatment in premenopausal patients with oestrogen receptor (ER)–positive tumours, regarding breast cancer–free interval (BCFi) and distant recurrence–free interval (D-RFi), with 30 years of follow-up and for specified intervals. Moreover, we aimed to investigate the effects of adjuvant tamoxifen on the incidence of secondary malignancies and survival after distant recurrence. Methods: Premenopausal patients with primary breast cancer were randomised to 2 years of tamoxifen (n = 277) or no systemic treatment (n = 287), irrespective of ER status. Information regarding events was collected by a review of medical records and from national registers. Results: The median follow-up for all patients without events was 28 years, and only four of the patients alive had a follow-up of <20 years. With 30 years of follow-up, tamoxifen prolonged BCFi in the intention-to-treat population (hazard ratio [HR] = 0.76, 95% confidence interval (CI) 0.61–0.94, p = 0.011) compared with no treatment. In patients with ER-positive tumours (n = 362), tamoxifen prolonged BCFi (HR = 0.62, 95% CI 0.47–0.82, p = 0.001) and D-RFi (HR = 0.73, 95% CI 0.54–0.99, p = 0.043). The positive effect on BCFi was significant also for the interval >15–30 years (HR = 0.53, 95% CI 0.28–0.98, p = 0.042). For patients with ER-positive tumours who were diagnosed with distant recurrence (n = 165), survival after distant recurrence was shorter among tamoxifen-treated patients (median, 29 months versus 43 months). The incidence of contralateral breast cancer was 42% lower in the tamoxifen group (HR = 0.58, 95% CI 0.35–0.96, p = 0.035), whereas no differences were observed regarding other secondary malignancies. Conclusions: With three decades of follow-up, 2 years of adjuvant tamoxifen reduced the incidence of breast cancer–related events and distant recurrence, and the carryover effect seems to extend beyond 15 years. Moreover, adjuvant tamoxifen seems to be associated with shorter survival after diagnosis of distant recurrence.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Bendahl, P. O.Lund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Personalized Breast Cancer Treatment,Lund University Research Groups,Lund Univ, Sweden(Swepub:lu)onk-pbe
(författare)
-
Fernö, M.Lund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Personalized Breast Cancer Treatment,Lund University Research Groups,Lund Univ, Sweden(Swepub:lu)onk-mfe
(författare)
-
Nordenskjöld, BoLinköpings universitet,Linköping University,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US(Swepub:liu)bono64
(författare)
-
Stål, OlleLinköpings universitet,Linköping University,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US(Swepub:liu)ollst87
(författare)
-
Rydén, L.Lund University,Lunds universitet,Bröstcancerkirurgi,Forskargrupper vid Lunds universitet,Breast Cancer Surgery,Lund University Research Groups,Skåne University Hospital,Lund Univ, Sweden; Skane Univ Hosp, Sweden(Swepub:lu)pat-lry
(författare)
-
Individuell BröstcancerbehandlingForskargrupper vid Lunds universitet
(creator_code:org_t)
-
South Swedish and South-East Swedish Breast Cancer Groups
Sammanhörande titlar
-
Ingår i:European Journal of Cancer: Elsevier BV110, s. 53-610959-80491879-0852
Internetlänk
Hitta via bibliotek
Till lärosätets databas